Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATH434 · PBT-434

Small molecule · developed by Alterity Therapeutics

Phase 2 Most advanced trial

ATHE Developer

2 Registered trials

What is ATH434?

ATH434 is an orally administered tablet given at 75 mg twice daily. It is being studied in multiple system atrophy, a neurodegenerative disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: PBT-434
Drug type: Small molecule
Therapy area: Neurology
Developer: Alterity Therapeutics (ATHE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: UK4JEM5WVX

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07729852	Phase 2	Multiple System Atrophy	Not yet recruiting	ATHE
NCT05109091	Phase 2	Multiple System Atrophy	Completed	ATHE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple System Atrophy

Sources

ClinicalTrials.gov NCT07729852

Updated Oct 11, 2026. Something wrong or missing? Report it on the ATHE page.

Follow ATHE, the company behind ATH434

See ATHE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATHE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z